Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 11/2015

01-11-2015 | Research Article

Surgery combined with chemotherapy for recurrent gastric cancer achieves better long-term prognosis

Authors: F. Kong, Y. Qi, H. Liu, F. Gao, P. Yang, Y. Li, Y. Jia

Published in: Clinical and Translational Oncology | Issue 11/2015

Login to get access

Abstract

Backgrounds

Recurrence is the most important factor associated with death of gastric cancer patients after surgery. The aim of this study was to explore the prognosis factors and the effective therapy for recurrent gastric cancer (RGC) patients after radical resection.

Methods

The clinical data of 144 RGC patients who underwent radical resection from January 1999 to March 2004 were reviewed. The 15 clinicopathological factors and treatment modalities on the survival were analyzed. Univariate and multivariate analyses were performed to investigate the prognostic significance of these factors for RGC.

Results

The early recurrence (<2 years) was found in 90 patients, while late recurrence (≥2 years) occurred in 54 patients. The 2-year cumulative survival rates were 23.8 % for recurrent patients receiving chemotherapy plus surgery vs. 1.2 % in patients having chemotherapy only (p < 0.001), while the median survival time was 11.0 months vs. 6.0 months (p < 0.001). Multivariate analysis indicated TNM stage after the first operation (p = 0.048), iASPP overexpression (p = 0.013), time to recurrence (p < 0.001) and treatment of recurrence (p < 0.001) as independent prognostic factors.

Conclusions

Surgery combined with chemotherapy for recurrent gastric cancer patients achieves ideal long-term prognosis, which should perform actively.
Appendix
Available only for authorised users
Literature
1.
2.
Liu C, Zhang R, Lu Y, Li H, Lu P, Yao F, et al. Prognostic role of lymphatic vessel invasion in early gastric cancer: a retrospective study of 188 cases. Surg Oncol. 2010;19:4–10.CrossRefPubMed
3.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed
4.
Xu AM, Huang L, Zhu L, Wei ZJ. Significance of peripheral neutrophil-lymphocyte ratio among gastric cancer patients and construction of a treatment-predictive model: a study based on 1131 cases. Am J Cancer Res. 2014;4:189–95.PubMedCentralPubMed
5.
Buzzoni R, Bajetta E, Di Bartolomeo M, Miceli R, Beretta E, Ferrario E, et al. Pathological features as predictors of recurrence after radical resection of gastric cancer. Br J Surg. 2006;93:205–9.CrossRefPubMed
6.
7.
Xu DZ, Geng QR, Long ZJ, Zhan YQ, Li W, Zhou ZW, et al. Positive lymph node ratio is an independent prognostic factor in gastric cancer after d2 resection regardless of the examined number of lymph nodes. Ann Surg Oncol. 2009;16:319–26.CrossRefPubMed
8.
Bilici A, Selcukbiricik F. Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer who underwent curative gastrectomy. Tumour Biol. 2015. doi:10.​1007/​s13277-015-3304-7.
9.
Choi JY, Ha TK, Kwon SJ. Clinicopathologic characteristics of gastric cancer patients according to the timing of the recurrence after curative surgery. J Gastric Cancer. 2011;11:46–54.PubMedCentralCrossRefPubMed
10.
Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S. Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer. 2000;89:255–61.CrossRefPubMed
11.
Mal F, Perniceni T, Levard H, Denet C, Validire P, Gayet B. Pre-operative predictive factors of early recurrence after resection of adenocarcinoma of the esophagus and cardia. Gastroenterol Clin Biol. 2005;29:1275–8.CrossRefPubMed
12.
Marrelli D, De Stefano A, de Manzoni G, Morgagni P, Di Leo A, Roviello F. Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study. Ann Surg. 2005;241:247–55.PubMedCentralCrossRefPubMed
13.
Li JH, Zhang SW, Liu J, Shao MZ, Chen L. Review of clinical investigation on recurrence of gastric cancer following curative resection. Chin Med J (Engl). 2012;125:1479–95.
14.
Lu B, Guo H, Zhao J, Wang C, Wu G, Pang M, et al. Increased expression of iASPP, regulated by hepatitis B virus X protein-mediated NF-kappaB activation, in hepatocellular carcinoma. Gastroenterology. 2010;139(2183–2194):e2185.
15.
Chen J, Xie F, Zhang L, Jiang WG. iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway. BMC Cancer. 2010;10:694.PubMedCentralCrossRefPubMed
16.
Kong F, Shi X, Li H, Li P, Yu J, Li X, et al. Increased expression of iASPP correlates with poor prognosis in FIGO IA2-IIA cervical adenocarcinoma following a curative resection. Am J Cancer Res. 2015;5:1217–24.PubMedCentralPubMed
17.
La Torre M, Rossi Del Monte S, Ferri M, Cosenza G, Mercantini P, Ziparo V. Peritoneal washing cytology in gastric cancer. How, when and who will get a benefit? A review. Minerva Gastroenterol Dietol. 2011;57:43–51.PubMed
18.
Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg. 2000;87:353–7.CrossRefPubMed
19.
Wu CW, Lo SS, Shen KH, Hsieh MC, Chen JH, Chiang JH, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg. 2003;27:153–8.PubMed
20.
Gunderson LL. Gastric cancer–patterns of relapse after surgical resection. Semin Radiat Oncol. 2002;12:150–61.CrossRefPubMed
21.
Li G, Wang R, Gao J, Deng K, Wei J, Wei Y. RNA interference-mediated silencing of iASPP induces cell proliferation inhibition and G0/G1 cell cycle arrest in U251 human glioblastoma cells. Mol Cell Biochem. 2011;350:193–200.CrossRefPubMed
22.
Liu T, Li L, Yang W, Jia H, Xu M, Bi J, et al. iASPP is important for bladder cancer cell proliferation. Oncol Res. 2011;19:125–30.CrossRefPubMed
23.
Jiang L, Siu MK, Wong OG, Tam KF, Lu X, Lam EW, et al. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe. Clin Cancer Res. 2011;17:6924–33.CrossRefPubMed
24.
Liu Z, Zhang X, Huang D, Liu Y, Liu L, Li G, et al. Elevated expression of iASPP in head and neck squamous cell carcinoma and its clinical significance. Med Oncol. 2012;29:3381–8.CrossRefPubMed
25.
Cao L, Huang Q, He J, Lu J, Xiong Y. Elevated expression of iASPP correlates with poor prognosis and chemoresistance/radioresistance in FIGO Ib1-IIa squamous cell cervical cancer. Cell Tissue Res. 2013;352:361–9.CrossRefPubMed
26.
Irvin TT, Bridger JE. Gastric cancer: an audit of 122 consecutive cases and the results of R1 gastrectomy. Br J Surg. 1988;75:106–9.CrossRefPubMed
27.
Heberer G, Teichmann RK, Kramling HJ, Gunther B. Results of gastric resection for carcinoma of the stomach: the European experience. World J Surg. 1988;12:374–81.CrossRefPubMed
28.
Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg. 1988;75:110–2.CrossRefPubMed
29.
Miwa K, Miyazaki I, Sahara H, Fujimura T, Yonemura Y, Noguchi M, et al. Rationale for extensive lymphadenectomy in early gastric carcinoma. Br J Cancer. 1995;72:1518–24.PubMedCentralCrossRefPubMed
30.
Plukker JT, Kampschoer GH. Extended lymph-node dissection for gastric cancer: a challenge for better survival results. Neth J Surg. 1990;42:3–8.PubMed
31.
Kim JW, Hwang I, Kim MJ, Jang SJ. Clinicopathological characteristics and predictive markers of early gastric cancer with recurrence. J Korean Med Sci. 2009;24:1158–64.PubMedCentralCrossRefPubMed
32.
Lehnert T, Rudek B, Buhl K, Golling M. Surgical therapy for loco-regional recurrence and distant metastasis of gastric cancer. Eur J Surg Oncol. 2002;28:455–61.CrossRefPubMed
33.
de Liano AD, Yarnoz C, Aguilar R, Artieda C, Ortiz H. Surgical treatment of recurrent gastric cancer. Gastric Cancer. 2008;11:10–4.CrossRefPubMed
34.
Song KY, Park SM, Kim SN, Park CH. The role of surgery in the treatment of recurrent gastric cancer. Am J Surg. 2008;196:19–22.CrossRefPubMed
35.
Tanizawa Y, Bando E, Kawamura T, Tokunaga M, Kondo J, Taki Y, et al. Influence of a positive proximal margin on oral intake in patients with palliative gastrectomy for far advanced gastric cancer. World J Surg. 2011;35:1030–4.CrossRefPubMed
Metadata
Title
Surgery combined with chemotherapy for recurrent gastric cancer achieves better long-term prognosis
Authors
F. Kong
Y. Qi
H. Liu
F. Gao
P. Yang
Y. Li
Y. Jia
Publication date
01-11-2015
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 11/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1327-6

Other articles of this Issue 11/2015

Clinical and Translational Oncology 11/2015 Go to the issue

Research Article

Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction

Research Article

miR-448 negatively regulates ovarian cancer cell growth and metastasis by targeting CXCL12

Research Article

Systemic chemotherapy as a main strategy for liver metastases from gastric cancer

Research Article

MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer

Retraction Note

Retraction Note to: Profiling of differentially expressed microRNAs (miRNAs) during differentiation of rat hepatic oval cells (HOCs) into hepatocellular carcinoma (HCC) cells

Research Article

The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits